

**WHO Prequalification of In Vitro Diagnostics
PUBLIC REPORT**

**Product: STANDARD Q HIV/Syphilis Combo Test
WHO reference number: PQDx 0382-117-00**

STANDARD Q HIV/Syphilis Combo Test with product code **09HIV20D**, manufactured by **SD Biosensor, Inc., Rest-of-World regulatory version**, was accepted for the WHO list of prequalified in vitro diagnostics and was listed on 26 May 2020.

Summary of WHO prequalification assessment for STANDARD Q HIV/Syphilis Combo Test

	Date	Outcome
Prequalification listing	26 May 2020	listed
Dossier assessment	1 May 2020	MR
Site inspection(s) of the quality management system	24-26 May 2023 14-16 June 2023	MR
Product performance evaluation	Quarter 4-2019	MR

MR: Meets Requirements

Report amendments and product changes

This public report has since been amended. Amendments may have arisen because of changes to the prequalified product for which the WHO has been notified and has undertaken a review. Amendments to the report are summarized in the following table, and details of each amendment are provided below.

Public report amendment	Summary of amendment	Date of report amendment
2.0	<p>1. Addition of a manufacturer for Cutting, Assembly, Buffer Preparation & dispensing, sealing, printing, packing, and shipping process.</p> <p>2. Addition of suppliers for raw materials:</p> <ul style="list-style-type: none"> • Upper device, • Lower device, • Desiccant, • Aluminum Pouch, • Buffer bottle, • Capillary tube, • Lancet, 	7 March 2024

	<ul style="list-style-type: none"> • Alcohol swab, • Outer package/IFU/Label. <p>3. Changes to the Outer package, Instructions for Use (IFU) and labels.</p>	
3.0	The addition of the manufacturing site is located in the public report of Plot no. 38, Sector 4, IMT Manesar, Gurugram, Haryana 122052, India.	7 May 2024

Intended use

According to the claim of intended use from SD Biosensor Inc., "*STANDARD Q HIV/Syphilis Combo Test is a rapid chromatographic immunoassay for the qualitative detection of antibodies specific to HIV-1 including subtype O, HIV 2 and Syphilis (*Treponema pallidum*) in human serum, plasma or whole blood. The test is for in vitro diagnostic use and intended as an aid to early diagnosis of HIV and Syphilis infection for HIV or Syphilis infected patients, patients with signs and symptoms for HIV and Syphilis and persons at risk. It provides only an initial screening test result. More specific alternative diagnosis methods should be performed in order to obtain the confirmation of HIV Virus and Syphilis infection.*"

Assay description

According to the claim of assay description from SD Biosensor Inc, "*STANDARD Q HIV/Syphilis Combo Test has "H1", "H2", "SYP" and "C" line region pre-coated with recombinant HIV-1 GP41 protein / recombinant HIV-1 subtype O GP41, recombinant HIV-2 GP36 protein, recombinant p17 *Treponema pallidum* protein (recombinant TPP 17 protein) and monoclonal anti-HIV-1 / monoclonal anti-syphilis respectively. The anti-HIV-1/anti-HIV-1 subtype O in patient sample interacts with the recombinant HIV-1 GP41-gold / recombinant HIV-1 subtype O GP41-gold and the anti-HIV-2 in patient sample interacts with the recombinant HIV-2 GP36-gold in the conjugation pad. The anti-syphilis in patient sample interacts with the recombinant TPP 17 protein-gold. The complex moves along the membrane chromatographically with assay diluent and is captured by the recombinant HIV-1 and HIV-2 antigens and/or recombinant TPP 17 antigen on the each test line (H1, H2, SYP). If the antibodies against HIV 1/ 2 and/or syphilis are in the patient sample, visible lines are formed in the each test line. The control line should always appear if the test procedure is performed properly.*"

Test kit contents

Component	25 tests (product code 09HIV20D)
Test device (individually in a foil pouch with desiccant)	25
Buffer Bottle	1 x 4 mL
Capillary tube (20µl)	Pack of 25
Instructions for use	1
Sterile lancet	25
Alcohol swabs	25

Items required but not provided

- Micropipette and tip
- Blood collection tube
- PPE (Personal Protective Equipment)
- Biohazard container
- Timing device

Storage

The test kit should be stored at 2-40°C.

Shelf-life upon manufacture

24 months.

Warnings/limitations

Please refer to the IFU attached to this public report.

Prioritization for Prequalification

Based on the established eligibility criteria, STANDARD Q HIV/Syphilis Combo Test was given priority for the WHO prequalification assessment.

Dossier assessment

SD Biosensor Inc. submitted a product dossier for STANDARD Q HIV/Syphilis Combo Test as per the “Instructions for compilation of a product dossier” (PQDx_018 version 3). The information (data and documentation) submitted in the product dossier was reviewed by WHO staff and external technical experts (assessors) appointed by WHO.

The Manufacturer's responses to the non-conformities found during the dossier review were accepted on 1 May 2020.

Commitment for Prequalification

SD Biosensor, Inc. committed to providing the interim study report and raw data for device stability studies on 24 November 2020 and the final report and raw data on 23 March 2022.

Based on the product dossier screening and assessment findings, the product dossier for STANDARD Q HIV/Syphilis Combo Test meets WHO prequalification requirements.

Manufacturing site inspection

An inspection of SD Biosensor Inc., located at 74, Osongsaengmyeong 4-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 28161, Republic of Korea was conducted between 24-26 May 2023 and Plot no. 38, Sector 4, IMT Manesar, Gurugram, Haryana 122052, India between 14-16 June 2023. At the time of considering the product application for Prequalification, the Manufacturer of the product had a well-established quality management system and manufacturing practices in place that would support the manufacture of the product of consistent quality. Routine inspections of the Manufacturer will be conducted with copies of these WHO Public Inspection Reports (WHOPIRs) published on the WHO Prequalification web page as per Resolution WHA57.14 of the World Health Assembly. Note that a WHOPIR reflects the information on the most current inspection performed at a manufacturing site for in vitro diagnostic products and gives a summary of the inspection findings.

Information on the most current inspection can be found at:

<https://extranet.who.int/prequal/inspection-services/prequalification-reports/whopirs-vitro-diagnostics>

All published WHOPIRs are with the manufacturer's agreement.

Product performance evaluation

STANDARD Q HIV/Syphilis Combo Test was evaluated at the Institute of Tropical Medicine, Belgium, on behalf of WHO in the 4th quarter of 2019, according to protocol PQDx_150, version 4.1.

Clinical performance evaluation

In this limited laboratory-based evaluation of clinical performance characteristics, a panel of 400 serum/plasma specimens was used. The specimens were characterized using the following reference algorithms. For HIV: Vironostika HIV Ag/Ab (bioMérieux) and Enzygnost Anti-HIV 1/2 Plus (Siemens Healthcare Diagnostics) or Genscreen HIV-1/2 Version 2 (Bio-Rad) in parallel, followed by INNO-LIA HIV I/II Score (Fujirebio Inc.) on initially reactive specimens. For Treponema pallidum: Vitros Syphilis TPA Assay (Ortho Clinical Diagnostics), followed by SERODIA-TP.PA (Fujirebio Inc.).

Clinical performance characteristics in comparison with an agreed reference standard				
	HIV-1/2		Syphilis	
	Initial (95% CI)	Final (95% CI)	Initial (95% CI)	Final (95% CI)
Sensitivity % (N=200)	100 (98.2-100)	100 (98.2-100)	95.0 (91.0-97.6)	95.5 (91.6-97.9)
Specificity % (N= 200)	99.0 (96.4-99.9)	99.5 (97.2-100)	99.5 (97.2-100)	99.5 (97.2-100)
Invalid rate % (N= 400)	0%			
Inter-reader variability % (N= 400)	3.25%*		1.0%	

* All 13 disagreements on HIV-1/2 results were on the HIV-2 line in HIV-1 positive specimens.

Out of 200 HIV-1 positive specimens, STANDARD Q HIV/Syphilis Combo Test showed the presence of the HIV-2 line in 30 (15 %) specimens, although in most cases (n=28), the HIV-2 line was weaker than the HIV-1 line, which is interpreted as HIV-1 positive result according to the IFU of the assay.

Analytical performance evaluation

Analytical performance characteristics		
	HIV-1/2	Syphilis
Sensitivity during seroconversion in comparison with a benchmark assay (Enzygnost Anti-HIV 1/2 Plus)	Of a total of 52 specimens in 8 panel, 23 were detected by the assay under evaluation, versus 21 specimens detected by the benchmark assay (Enzygnost Anti-HIV 1/2 Plus). Seroconversion sensitivity index of -0.25. Therefore, detection is 0.25 specimens earlier than the benchmark assay.	Of a total of 9 specimens in 1 panel, 5 were detected by the assay under evaluation versus 2 specimens detected by the benchmark assay (Vitro Syphilis TPA Assay).
Analytical sensitivity on mixed titer panels	All 25 specimens of panel PRB-205 (SeraCare) were correctly classified.	All 17 specimens of panel PSS-202 (SeraCare) were correctly classified.
Analytical sensitivity on WHO reference preparation panels	All 6 HIV subtypes/groups in the 1 st International Reference Panel for anti-HIV (NIBSC code 02/210) were detected.	The 1 st International Standard for human syphilitic plasma IgG (NIBSC code 05/122) was detected.

Lot to lot variation on a dilution panel	Lot to lot variation was within +/- 1 two-fold dilutions for all 10 dilution series.	Lot to lot variation was within +/- 1 two-fold dilutions for all 10 dilution series.
--	--	--

Operational characteristics and ease of use

This assay does not require laboratory equipment and can be performed in laboratories with limited facilities or in non-laboratory settings.

The assay was found easy to use by the operators performing the evaluation.

Key operational characteristics	
Number of steps*	2 steps in total 1 step with precision pipetting (only for serum/plasma)
Time to result	15 minutes
Endpoint stability (interval)	5 minutes (the test can be read between 15 and 20 minutes after the addition of diluent)
Internal QC	Yes, reagent addition control

* Definition: each action required to obtain a result (excluding specimen collection, device preparation – opening the pouch), e.g. for RDTs: add specimen, add buffer (2 steps).

Based on these results, the performance evaluation for the STANDARD Q HIV/Syphilis Combo Test meets the WHO prequalification requirements.

Labelling


- 1. Labels**
- 2. Instructions for use**

1. Labels


1.1 Device Package Artwork

STANDARD Q

HIV/Syphilis Combo 25T




STANDARD Q HIV/Syphilis Combo 25T






STANDARD Q

HIV/Syphilis Combo 25T




1.2 Foil pouch







15mm Notch



15mm Notch

1.3 Buffer labels



1.4 Inverted cup(5 μl) label**Capillary tube (20 μl)**

LOT No.:



EXP :

Quantity : 25PCS

L46RT1ENR1
Issue date: 2020.02**1.5 Sterile Lancet labels****Disposable Sterile Lancets** LOT No. : XXXXXX

Product code : 01GL27

 MFG Date : YYYY.MM.DD.**25PCS
28G** EXP Date : YYYY.MM.DD.B05SL2ENR0
Issue Date : 2020.07**INTENDED USE**

To obtain a capillary blood specimen from the fingertip.

INSTRUCTIONS FOR USE

To use, twist-off the protective cap.

CAUTION

The lancet is guaranteed sterile while protective cap is sealed to the base.

Do not use if the seal has been damaged or broken.

**Manufactured by**

Tianjin Huahong Technology Co., Ltd.
A01, Plant B No. 278, Hangkong Road,
Tianjin Pilot Free Trade Zone
(Air Port Industrial Park),
300308 Tianjin, China

**Authorized Representative**

Shanghai International Holding Corp.
GmbH (Europe)
Eiffestrasse 80, 20537 Hamburg, Germany
Tel:+49-40-2513175




STERILE





1.6 Alcohol swab labels



Front



Back




PANTONE Reflex Blue U

PANTONE Orange 021 U

2@ 3@ 4@ 5@ 6@ 7@ 8@



2@ 3@ 4@ 5@ 6@ 7@ 8@



2. Instructions for use¹

¹ English version of the IFU was the one that was assessed by WHO. It is the responsibility of the manufacturer to ensure correct translation into other languages.


EN

REF QHSC01B
Cat. No.: 09HIV20D

HIV/Syphilis Combo

STANDARD™ Q HIV/Syphilis Combo Test
PLEASE READ INSTRUCTIONS CAREFULLY BEFORE YOU
PERFORM THE TEST

KIT CONTENTS



MATERIALS REQUIRED BUT NOT PROVIDED

- ① Micropipette and tip ② Blood collection tube
- ③ PPE (Personal Protective Equipment) ④ Biohazard container

SPECIMEN COLLECTION AND STORAGE

- Serum**
1. Collect the venous blood into commercially available tubes WITHOUT anti-coagulant, and leave to settle for 30 minutes for blood coagulation and then centrifuge blood to get serum specimen of supernatant.
2. If serum in the plain tube is stored in a refrigerator at 2° - 8°C / 36° - 46°F, the specimen can be used for testing within 4 days after collection. For prolonged storage, it should be at below -40°C / -40°F.
3. It should be brought to room temperature prior to use.

- Plasma**
1. Collect the venous whole blood into the commercially available anti-coagulant tube such as heparin, EDTA or sodium citrate by venipuncture and centrifuge blood to get plasma specimen.
2. If plasma in an anti-coagulant tube is stored in a refrigerator at 2° - 8°C / 36° - 46°F, the specimen can be used for testing within 4 days after collection. For prolonged storage, it should be at below -40°C / -40°F.
3. It should be brought to room temperature prior to use.

- Whole blood**
[Capillary whole blood]
1. Capillary whole blood should be collected aseptically by fingertip.
2. Select the finger that is free from callus. Gently rub the finger to warm it to stimulate blood circulation.
3. Squeeze the end of the fingertip and pierce with a sterile lancet.
4. Collect the capillary whole blood to the black line of the capillary tube for the testing.
5. The capillary whole blood must be tested immediately after collection.


- Venous whole blood**
1. Collect the venous whole blood into the commercially available anti-coagulant tube such as heparin, EDTA or sodium citrate by venipuncture.
2. If venous whole blood in an anti-coagulant tube is stored in a refrigerator at 2° - 8°C / 36° - 46°F, the specimen can be used for testing within 1 - 2 days after collection.
3. Do not use hemolyzed blood specimen.

- * Anticoagulants such as heparin, EDTA or sodium citrate do not affect the test result.
• As relevant, interference, haemolytic specimens, rheumatoid factors-contained specimens and lipemic, icteric specimens can lead to impair the test results.

PREPARATION AND TEST PROCEDURE

■ Preparation


1. Carefully read the instructions for using the STANDARD Q HIV/Syphilis Combo Test.
2. Check the expiry date at the back of the foil pouch. Use another lot, if expiry date has passed.
3. Open the foil pouch, and check the test device and the color indicator desiccant pack in foil pouch.
4. Allow the STANDARD Q HIV/Syphilis Combo Test components and specimen to come to room temperature (15° - 30° C / 59° - 86°F) for 30 minutes prior to testing.
5. Check that the test device packaging is not damaged. If damaged, discard the test and use another test. If a humidity indicator inside shows saturation (color changed from orange to green), throw away the test device and take another test device packaging. If the color of the buffer bottle does not show a change, you can use the test. Throw away the buffer bottle in the non-sharps (non-infectious) desiccant container.
6. Procedure method should be followed for the specific specimen type being tested.



Test Procedure

1. Collecting of Specimen

- 1-1. For serum/plasma/venous whole blood specimen
Collect the 10 μl of serum/plasma and 20μl of venous whole blood specimen using a micropipette.



STANDARD Q HIV/Syphilis Combo Test	
HIV negative	HIV positive
Anti-HIV-1 positive/Anti-Tp negative	0
Anti-HIV-1/Anti-Tp positive	247
Anti-HIV-1 positive non-B subtype	0
Anti-HIV-2 positive	40
Sensitivity	100
637/637 = 100%	

PERFORMANCE CHARACTERISTICS

■ Diagnostic sensitivity

1. HIV Ab detection: The Diagnostic Sensitivity for anti-HIV antibody detection, calculated on 637 positive specimens, is 100% (637/637) with a Wilson 95% confidence interval of [99.4% - 100.0%].

STANDARD Q HIV/Syphilis Combo Test	
Syphilis negative	Syphilis positive
Anti-Tp/Anti-HIV positive	4
Anti-Tp positive/Anti-HIV negative	246
Sensitivity	395/400 = 98.8%

2. Syphilis Ab detection: The Diagnostic Sensitivity for anti-Treponema pallidum antibody detection, calculated on 400 positive specimens, is 98.8% (395/400) with a Wilson 95% confidence interval of [97.1% - 99.5%].

■ Diagnostic specificity:

■ Test

■ Control

■ Sample

■ Result

■ Conclusion

